

DMB

Display Date	9-7-99
Publication Date	9-8-99
Certifier	<i>[Signature]</i>

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D-0433]

Draft Guidance for Industry on Average, Population, and Individual Approaches to Establishing Bioequivalence; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Average, Population, and Individual Approaches to Establishing Bioequivalence." This draft guidance provides recommendations to sponsors and/or applicants intending to perform in vivo and in vitro bioequivalence (BE) studies based on comparisons of in vivo and in vitro bioavailability (BA) measures in investigational new drug applications, new drug applications, abbreviated new drug applications, and their amendments and supplements. This draft guidance is a modification of a preliminary draft guidance entitled "In Vivo Bioequivalence Studies Based on Population and Individual Bioequivalence Approaches" published in December 1997, and this draft guidance updates a July 1992 FDA guidance entitled "Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design". When finalized, this draft guidance will replace both the 1992 and 1997 guidances.

DATES: Written comments may be submitted on the draft guidance document by (*insert date 60 days after date of publication in Federal Register*). General comments on agency guidance documents are welcome at any time.

ADDRESSES: Copies of this draft guidance for industry are available on the Internet at "http://www.fda.gov/cder/guidance/index.htm". Submit written requests for single copies of "Average, Population, and Individual Approaches to Establishing Bioequivalence" to the Drug Information

Branch (HFD-210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the draft guidance to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.


FOR FURTHER INFORMATION CONTACT: Mei-Ling Chen, Center for Drug Evaluation and Research (HFD-870), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5919.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a draft guidance for industry entitled “Average, Population, and Individual Approaches to Establishing Bioequivalence.” The draft guidance provides recommendations to sponsors and/or applicants intending to perform in vivo and in vitro BE studies based on comparisons of in vivo and in vitro BA measurements. In an earlier guidance entitled “Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design,” FDA recommended that an average BE approach be used to establish BE between test and reference drug products. Because of the limitations in the average BE approach, and after extensive intramural and extramural discussions, the Center for Drug Evaluation and Research (CDER) now recommends that the average BE approach be supplemented by two new approaches, population and individual BE. This draft guidance focuses on how to use each approach once a specific criterion has been chosen.

This draft guidance is one of a set of seven core guidances being developed to provide recommendations on how to meet provisions of part 320 (21 CFR part 320) for orally administered drug products and drug products for local action. Taken together, the seven guidances are designed to clarify the studies needed to document product quality BA/BE for all drug products regulated by CDER in accordance with the provisions in part 320. A further intent is to reduce regulatory burden where feasible.


This level 1 draft guidance is being issued consistent with FDA's good guidance practices (62 FR 8961, February 2, 1997). It represents the agency's current thinking on average, population, and individual approaches to establishing BE. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such an approach satisfies the requirements of the applicable statutes, regulations, or both.

Interested persons may, at any time, submit written comments on the draft guidance to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number




found in brackets in the heading of this document. A copy of the draft guidance and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: 8/26/99
August 26, 1999



Margaret M. Dotzel
Acting Associate Commissioner for Policy

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL


[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

BILLING CODE 4160-01-F